Restoring conv 7→8. Overnight downgrade cited PE=733 — valid concern but PE known at conv-9 entry, not new info. What IS new: WSJ Heard on the Street (March 18) explicitly validates defense tech vs primes thesis: 'XAR (defense tech-heavy) +67% LTM vs ITA (prime-heavy) +54%'. Article says pentagon 2026 budget: legacy programs flat, AI/drones/space up 20%+. Cost asymmetry problem (1M missile vs 20K drone) accelerating shift to affordable autonomous systems — KTOS exact fit. Iran war escalation (Russia sharing drone tech, Fujairah bypass hit) extends conflict duration and demand. Position +8.8%. Stop trailing up to 83 to protect gains. Target 120.
Downgraded from 9. Defense tech with strong tailwinds (drone autonomy, hypersonics) and 24% analyst consensus upside. BUT: PE=733 signals market pricing in years of growth, no valid DCF (stale model shows $18 vs $95 price), and conv-9 requires validated catalyst within 90 days — none confirmed. Thesis intact, but overvaluation risk is real at current multiples.
RAISING 8→9. FY2025 actual: $1.347B revenue (+16.6% organic), EBITDA $119.9M (8.9%). CRITICAL: Northrop won MUX TACAIR CCA with Valkyrie as the aircraft — program of record confirmed. This removes primary de-risking condition. 2026 guidance: $1.595-1.675B (+21%), EBITDA ~10% (margin expansion). Hypersonic: new missile contract + ~$1B sole-source opportunity expected. Orbit Technologies closed for $352.7M — strategic space expansion. FCF negative (-$125M FY2025) but acceptable for growth phase. Stock at $89 (34% off 52w high), 32% upside to analyst consensus.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
FCF-Based Reverse DCF
70.4%/yr
±5.0% · FCF growth to justify current price
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Sole-source positions on BQM-177, BQM-167, and MQM-178 drone programs give locked-in revenue for 10+ years. Valkyrie selected as Northrop MUX CCA platform — first expendable combat drone program of record. $1.45B MACH TB 2.0 hypersonic contract is the largest in company history. 1.8x book-to-bill with $1.6B backlog growing into a $1.6B revenue guide for 2026.
69% fixed-price contracts in an inflationary labor environment create real margin squeeze risk. Still a $7B company competing with Lockheed, RTX, and Northrop for follow-on orders. Expendable drone unit economics are intentionally low-margin by design — thesis depends on volume scaling faster than costs.
Valkyrie program cancellation, fixed-price margin compression below 10%, loss of sole-source target drone contracts
Updated Mar 11
Kratos awarded M NSWC PHD contract for Oriole rocket motors and thrust vector control systems supporting Navy missile and test programs. Also appointed David King to Board. Contract flow continues to ...
KTOS won .8M Space Force award for medium missile tracking ground system and M NSWC Oriole rocket motor contract this week. Airbus Valkyrie first flight prep underway. Stock pulled back on 650x P/E co...
Sole-source franchise model with Valkyrie as first CCA Program of Record. CEO signals two additional sole-source tactical drone wins late 2026. MACH TB 2.0 hypersonic call option. Conviction 8/10 at $...
Kratos disclosed March 3 production contract for ~$7M Counter-UAS system. Stock +6.7% on contract wins and growth outlook, then dropped following Red Cat negative news that may be a buying opportunity...
KTOS rallied 6.7% mid-week on contract wins and Valkyrie program optimism. Gave back ~5% Thursday after drone peer Red Cat (RCAT) reported larger-than-expected losses — sector sentiment drag, not KTOS...
KTOS surged 6.7% on March 17-18 driven by ongoing contract wins (Counter-UAS, SDA fire control, drone collaborations) and fresh growth outlook from analysts. Valkyrie tactical drone program advancing....
KTOS surged 5.88% on Q4 earnings beat. New ~M Counter-UAS production contract, Space Development Agency Advanced Fire Control program completing Critical Design Review, drone collaborations expanding....
FY2025 results confirm thesis: .347B revenue (+18.5%), EBITDA .9M (8.9%). FY2026 guidance .635B midpoint (+21%). Three franchise-level programs — Valkyrie CCA (Program of Record), MACH TB 2.0 (.45B hy...
FY2025: $1.347B revenue (+16.6% organic), $119.9M EBITDA (8.9%). 2026 guidance $1.595-1.675B, EBITDA ~10%. CRITICAL: Northrop won MUX TACAIR CCA with Valkyrie as the aircraft — program of record confi...
KTOS: $1.57B backlog (1.8x book-to-bill), $870M revenue, backlog-driven growth. Valkyrie + target drones + hypersonic (MACH TB 2.0 $1.45B) core growth drivers. Moat: first-to-market, design-in positio...